IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3645
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$340M
Allan Marshall
Upexi, Inc. engages in the development, manufacture, and distribution of consumer products. It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand name. The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform. It also focuses on cryptocurrency industry and management of cash assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. Upexi, Inc. was incorporated in 2018 and is headquartered in Tampa, Florida.
Headcount
59
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = UPXI ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$UPXI UPEXI, INC. | 39 | 59 | 75 | 7 | - | 1.2x | -240.8% | -43.3% | 74.1% | -392.4% | -413.4% | 84.8% | 0.0% | 457.0x | $340M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
UPEXI, INC. (UPXI) receives a "Avoid" rating with a composite score of 39.2/100. It ranks #3645 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Allan Marshall
Chief Executive Officer
Labor Force
59
59
17
31
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for UPXI
HQ Base
Pending Verification
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for UPXI.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -240.8% (sector -2.5%)
GM 74% vs sector 43%, OM -392% vs sector 1%
Capital turnover N/A
Rev growth 85%, 6yr history
Interest coverage -9868.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags UPEXI, INC. with an Avoid rating, assigning a composite score of 39.2/100 and 1 out of 5 stars. Ranked #3645 of 7,333 stocks, UPXI falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
With a quality score of 59/100, UPXI shows adequate but unremarkable business quality. The company reports a return on equity of -240.8% (sector avg: -2.5%), gross margins of 74.1% (sector avg: 42.5%), net margins of -413.4% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
UPXI carries a solid value score of 75/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include an EV/EBITDA of 1.21x, a P/B ratio of 0.88x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
UPEXI, INC.'s investment score of 17/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 84.8% vs. a sector average of 5.9% and a return on assets of -43.3% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
UPEXI, INC. is experiencing notably weak momentum with a score of just 7/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 84.8% year-over-year, while a beta of -0.10 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
UPXI's stability score of 31/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -0.10 and a debt-to-equity ratio of 457.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
UPEXI, INC.'s short interest score of 32/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 457.00x), small-cap liquidity risk. At $340M (small-cap), UPXI carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
UPEXI, INC. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3645 of 7,333 overall (50th percentile). Key comparisons include ROE of -240.8% trailing the -2.5% sector median and operating margins of -392.4% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While UPXI currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (7) would have the largest impact on the composite score.
EV/EBITDA 89% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 9610% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 74% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate UPEXI, INC. (UPXI) as Avoid with a composite score of 39.2/100 at a current price of $0.60. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (75th percentile) and quality (59th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (7th percentile) and investment (17th percentile) tempers our overall conviction. We assign a No Moat rating (20/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
UPEXI, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.2/100 places it at rank #3645 in our full 7,333-stock universe. At $340M in market capitalization, UPEXI, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 85%, though momentum at the 7th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 74% (+31.6pp vs sector) narrow to operating margins of -392% (-393.7pp vs sector) and net margins of -413.4%, yielding a gross-to-net conversion rate of -558%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.60, UPEXI, INC. appears undervalued relative to its fundamentals. Our value factor score of 75/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at EV/EBITDA of 1.2x (discounted to peers), P/B of 0.9x, P/S of 1.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 74% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 85% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 75/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
The Avoid rating (composite 39.2/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (457% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
We assign a High uncertainty rating to UPEXI, INC.. Key risk factors include significant leverage (457% debt-to-equity), current negative profitability (net margin -413.4%), below-average price stability (31th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (457% debt-to-equity); current negative profitability (net margin -413.4%); below-average price stability (31th percentile); low beta of -0.10 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 31th percentile and quality factor at the 59th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 74% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate UPEXI, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-240.8%), elevated leverage (457% D/E), negative profitability, weak asset returns (ROA -43.3%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — UPEXI, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, UPEXI, INC. receives a Avoid rating with a composite score of 39.2/100 (rank #3645 of 7,333). Our quantitative framework assigns a No Moat (20/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 38/100.
Our analysis does not support a constructive view on UPEXI, INC. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign UPEXI, INC. a meaningful economic moat, scoring 20/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10.4/20.
The strongest moat sources are margin superiority (10.4/20) and growth durability (9.5/20). GM 74% vs sector 43%, OM -392% vs sector 1%. Rev growth 85%, 6yr history. These pillars form the core of UPEXI, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROE proxy -240.8% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect UPEXI, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 74% providing a solid profitability foundation, robust top-line growth of 85% expanding the revenue base. The margin cascade from 74% gross to -392% operating to -413.4% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 59th percentile.
The margin profile shows gross margins of 74%, operating margins of -392%, net margins of -413.4%. Return metrics include ROE of -240.8% and ROA of -43.3%. Relative to the Manufacturing sector, gross margins are 31.6 percentage points above the sector median of 43%, and ROE of -240.8% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 457%, which may limit financial flexibility, revenue growth of 85%. The sector median D/E is 0%, putting UPEXI, INC. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Thin net margins of -413.4% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (7th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Above 50MA
37.18%
Net New Highs
+51081
The recent price decline of 33% in Upexi, Inc.'s ( NASDAQ:UPXI ) stock may have disappointed insiders who bought...
Upexi (UPXI) Q2 2026 earnings call recap: Solana treasury strategy, yield plans, capital discipline, and volatility risks amid big unrealized losses—read...

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. Herbalife posted adjusted earnings of 28 cents per share, missing market estimates of 39 cents per share. The company’s quarterly sales came in at $1.22 billion versus expectations of $1.19 billion. Herbalife shares dipped 35.7% to $7.55 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers JX Luxventure Limited (NASDAQ: JXJT) shares jumped 377% to $6.21 following H1 results. Dunxin Financial Holdings Limited (NYSE: DXF) surged 204% to $1.11 after gaining around 5% on Wednesday. China Natural Resources, Inc. (NASDAQ: CHNR) jumped 143% to $2.68 after gaining around 10% on Wednesday. The Children's Place, Inc. (NASDAQ: PLCE) rose 101% to $29.23. Nano-X Imaging Ltd. (NASDAQ: NNOX) shares climbed 54.7% to $9.84. Nvidia reported a 59,632 share stake in Nano X Imaging. RiskOn International, Inc. (NASDAQ: ROI) gained 54% to $0.1710. SoundHound AI, Inc. (NASDAQ: SOUN) gained 53% to $3.4499. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the company disclosed positions in several companies, including SoundHound AI. Orgenesis Inc. (NASDAQ: ORGS) climbed 30.2% to $0.4362. Orgenesis 10% owner Jacob Safier acquired a total of 365,140 shares at an average price of $0.58. Pegasystems Inc. (NASDAQ: PEGA) jumped 27.8% to $64.84 after the company reported better-than-expected fourth-quarter financial results and issued FY24 EPS and revenue guidance above estimates. JFrog Ltd. (NASDAQ: FROG) shares gained 27% to $47.09 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS and revenue guidance above estimates. Infobird Co., Ltd (NASDAQ: IFBD) rose 26% to $1.1800. American Well Corporation (NASDAQ: AMWL) jumped 25% to $1.39 following quarterly results. Datasea Inc. (NASDAQ: DTSS) gained 25% to $11.24. DataSea announced a $30 million 5G multimodal communication technology service agreement. AppLovin Corporation (NASDAQ: APP) rose 22% to $57.16 after the company reported ...

Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results. AppLovin reported quarterly earnings of 49 cents per share which beat the analyst consensus estimate of 36 cents. The company reported quarterly sales of $953.26 million, beating the analyst consensus estimate of $928.17 million. AppLovin shares jumped 22.3% to $57.30 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers China Natural Resources, Inc. (NASDAQ: CHNR) gained 409% to $5.60 in pre-market trading after gaining around 10% on Wednesday. Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA) shares jumped 70.2% to $1.89 in pre-market trading after surging around 19% on Wednesday. SoundHound AI, Inc. (NASDAQ: SOUN) gained 69.8% to $3.83 in pre-market trading. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the ...
Operator: Good day. Welcome to Upexi, Inc. Fiscal Second Quarter 2026 Financial Results Conference Call. Please note this event is being recorded.